KCNA3 and rheumatoid arthritis: In particular, dalazatide is a potassium channel (Kv1.3) blocker and has successfully completed Phase 1 within clinical trials and is about to enter Phase 2 of the trials for the treatment of multiple sclerosis and rheumatoid arthritis [203].